Detailed narrative
Strategic Transition and Portfolio Diversification
Incyte is undergoing a strategic transition to evolve beyond its cornerstone product, Jakafi, aiming for a high-quality, growth-oriented portfolio across hematology, oncology, and immunology. This involves continued organic growth from existing commercial products, life cycle launches of key brands, advancement of a broad late-stage pipeline, and a focused approach to business development. The company expects its I&I portfolio to contribute approximately one-third of total revenue by 2030, and the core business ex-Jakafi to approach $3 billion to $4 billion by the same year.
Povorcitinib Advancements in HS and Vitiligo
The FDA accepted the regulatory application for povorcitinib in moderate to severe hidradenitis suppurativa (HS) ahead of schedule, supported by robust Phase III data in both pre- and post-biologic patient populations. Positive results were also announced from two Phase III studies for povorcitinib in nonsegmental vitiligo, demonstrating statistically significant and clinically meaningful reductions in facial vitiligo. These results will support a regulatory application in H1 2027, with potential approvals and launches in early 2027 for HS and vitiligo, positioning povorcitinib as a significant growth driver.
Pipeline Progress in Hematology and Oncology
In hematology, Incyte is on track to initiate a Phase III study for 989 (mutant CALR antibody) in previously treated ET patients by midyear, following a positive end-of-phase meeting with the FDA. The company also initiated a Phase I dose escalation study for 058 (JAK2 V617F inhibitor) ASD formulation in MPN patients. In oncology, a Phase III study for KRAS G12D inhibitor 734 in first-line pancreatic cancer is underway, targeting a significant unmet need. Additionally, pivotal trials are advancing for A90 in colorectal cancer and 667 in ovarian cancer.
Commercial Performance and Growth Drivers
Total revenue for Q1 FY26 was $1.27 billion, up 21% year-over-year, with net sales of $1.1 billion, up 20%. Jakafi sales reached $758 million, a 7% increase, driven by broad growth across indications. The core business excluding Jakafi grew 63% year-over-year, with Opzelura contributing $143 million (up 20%). Niktimvo, Monjuvi, and Zynyz also showed strong growth, with Niktimvo capturing 32% of the third-line plus market within 12 months of launch.
Management Team Enhancements
Incyte announced several executive appointments to strengthen its leadership team for the next phase of growth. Suky Upadhyay was appointed Chief Financial Officer, Pablo Cagnoni as President, Incyte and Global Head of Research and Development, and Steven Stein as Executive Vice President and Chief Medical Officer and Head of Late-stage Development. Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, coinciding with the integration of U.S. commercial operations to create a launch-ready organization.
Opzelura's Market Position and Future
Opzelura continues to be a major contributor, with strong US prescription demand up 17% year-over-year and international growth robust in vitiligo. The brand is under review in Europe for moderate AD, with approval and launch expected in H2 2026. Management believes Opzelura can achieve approximately $1.3 billion in sales by 2030, driven by continued penetration in AD and vitiligo, the upcoming launch in mild to moderate HS, and European expansion.